For example, should patients with the homozygous variant GSTP1 genotype receive lower doses as an attempt to reduce their risk of severe neutropenia, and therefore avoid treatment delays or interruption that could compromise the final response outcomes? This evidence concerns the gene GSTP1 and neutropenia.